Strand Life Sciences launched StrandAdvantage for timely genomic profiling results
With medical technology making better strides in different fields, Strand Life Sciences has launched StrandAdvantage, a cancer tissue-specific genomic profiling service to provide oncologists with clinically actionable and timely results for first-line therapy decisions.
Strand Life Sciences is a global genomic profiling company that uses next generation sequencing technology to empower personalized cancer care. The StrandAdvantage test provides standard-of-care tissue-specific results for non-small cell lung (NSCLC), breast and colon carcinomas within 10 working days. This helps in guiding oncologists in planning their treatment as well.
Cancer is a disease affected by multiple variations within genes. Information from single gene tests is often limited and oncologists increasingly want greater depth of information about patients’ tumors. StrandAdvantage tests all the relevant genes upfront, thereby helping the oncologist select a targeted therapy for first-line or subsequent treatment.
StrandAdvantage accelerates the analysis of therapeutically actionable cancer genes in solid tumors, and matches them to relevant National Comprehensive Cancer Network (NCCN)-recommended cancer therapies, enabling timely decisions for patient-specific treatments. Strand’s NGS-based genomic profiling service provides a comprehensive view of genomic changes in an easy-to-read report enabling oncologists to make optimized, first-line treatment decisions. The service also provides an extended investigation ‘on-demand’ report after 15 days for cases that require a complete workup of all major gene variants and pathways known to be impacted by existing targeted therapies.
Scott A. Storrer, Global Chief Executive Officer and President, Strand Life Sciences said: “StrandAdvantage will provide oncologists with cancer tissue-specific genomic information about their patients’ solid tumors and help in guiding first-line therapy decisions. Our genomic profiling service enables the patient to start treatment in days instead of weeks by quickly providing relevant, clinically actionable results. The extended StrandAdvantage report provides an unmatched depth of analysis that includes cancer sub type as well as tissue type.”